The impact of semaglutide on liver fat assessed by serial cardiac CT scans in patients with type 2 diabetes: Results from STOP trial

By sjmartinez • April 27, 2025

Golub LS, Manubolu VS, Aldana-Bitar J, Dahal S, Verghese D, Alalawi L, Krishnan S, Kianoush S, Benzing T, Ichikawa K, Kinninger A, Fazlalizadeh H, Pourafkari L, Ahmad K, Susarla S, Mangaoang C, Ghanem AK, Javier DA, Hamal S, Roy SK, Budoff MJ. The impact of semaglutide on liver fat assessed by serial cardiac CT scans in patients with type 2 diabetes: Results from STOP trial. Nutr Metab Cardiovasc Dis. 2025 Apr 5:104036. doi: 10.1016/j.numecd.2025.104036. Epub ahead of print. PMID: 40287313.

Tags: ASCVD, atherosclerotic cardiovascular disease, CAC, Cardiology/Epi, cardiovascular disease, Computed Tomography Angiography, coronary artery calcium, CTA, CVD, General Internal Medicine, GLP1 receptor agonists, Harbor UCLA, HCC, Hepatocellular carcinoma, MASH, MASLD, Metabolic dysfunction-associated Steatohepatitis, Metabolic dysfunction-associated steatotic liver disease, Publications, randomized trial, Resident, semaglutide

Scalable generation of hematopoietic stem cell-engineered off-the-shelf mono-specific cytotoxic T cells targeting solid tumors

Zhu Y, Yu J, Kim YJ, Tian Y, Li Z, Chen Y, Lyu Z, Zhu E, Zhao AS, Ma N, Zhang C, Kramer A, Wilson[...]

Timing of Parenteral Nutrition in Neonates, Infants, and Children: Current Evidence, Circadian Considerations, and Emerging Directions

Chan AP, Lai RW, Calkins KL. Timing of Parenteral Nutrition in Neonates, Infants, and Children: Current Evidence, Circadian Considerations, and Emerging Directions. Nutrients. 2026 Aug[...]

Opportunistic Chest CT Paraspinal Muscle Biomarkers to Predict Longitudinal Thoracic Vertebral Bone Mineral Density Loss: Results from MESA

Hathaway QA, Ghotbi E, Pan T, Momtazmanesh S, Klein JG, Allison M, Barbosa EJM Jr, Barr RG, Bluemke DA, Lima JAC, Post W, Tison GH,[...]